Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

ABSTRACT:

Background

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC).

Methods

Patients with histologically proven HCC and not amenable to curative or liver directed therapy were included in this 2-stage phase 2 trial. Eligibility included an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and Child's Pugh score of A or B, and 1 prior systemic therapy. Patients received erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days. Objective tumor response was the primary end point.

Results

Twenty-seven patients with advanced HCC (median age, 60 years) were enrolled in this multi-institutional study. The proportion of patients with Ch

SUBMITTER: Philip PA 

PROVIDER: S-EPMC3896238 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature